{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Toripalimab&page=2", "query": { "intervention": "Toripalimab", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Toripalimab&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-18T06:40:52.843Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07140679", "title": "Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Localized Colon Carcinoma", "Stage IIB Colon Cancer AJCC v8", "Stage IIC Colon Cancer AJCC v8", "Stage III Colon Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Colonoscopy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Toripalimab", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2025-09-19", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-09-18T06:40:52.843Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Johns Creek, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Johns Creek", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07140679" }, { "nct_id": "NCT05635643", "title": "Study of CHS-114 in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "CHS-114", "type": "DRUG" }, { "name": "toripalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Coherus Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2022-12-15", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-18T06:40:52.843Z", "location_count": 12, "location_summary": "Palo Alto, California • Atlanta, Georgia • Louisville, Kentucky + 9 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05635643" }, { "nct_id": "NCT05479045", "title": "A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer Stage IV", "Ovarian Cancer Stage III", "Ovarian Cancer Stage 3" ], "interventions": [ { "name": "NY-ESO-1 Peptide vaccine", "type": "BIOLOGICAL" }, { "name": "Toripalimab-tpzi", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 24, "start_date": "2026-09", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-09-18T06:40:52.843Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Hackensack, New Jersey", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05479045" }, { "nct_id": "NCT04645069", "title": "ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced/Metastatic Solid Tumors" ], "interventions": [ { "name": "ADG126 Mono", "type": "BIOLOGICAL" }, { "name": "ADG126-anti PD1", "type": "BIOLOGICAL" }, { "name": "ADG126-ADG106", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Adagene Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2021-03-15", "completion_date": "2024-05-17", "has_results": false, "last_update_posted_date": "2024-08-14", "last_synced_at": "2026-09-18T06:40:52.843Z", "location_count": 2, "location_summary": "Los Angeles, California • San Antonio, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04645069" }, { "nct_id": "NCT06975293", "title": "STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Sarcoma", "Leiomyosarcoma", "Dedifferentiated Liposarcoma" ], "interventions": [ { "name": "STC-15 in combination with toripalimab", "type": "COMBINATION_PRODUCT" }, { "name": "STC-15 monotherapy", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "STORM Therapeutics LTD", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2025-05-05", "completion_date": "2028-06-29", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-18T06:40:52.843Z", "location_count": 10, "location_summary": "San Francisco, California • Boston, Massachusetts • Grand Rapids, Michigan + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06975293" }, { "nct_id": "NCT07281716", "title": "Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Microsatellite Stable Colorectal Carcinoma" ], "interventions": [ { "name": "Nadunolimab", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dan Feng", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2025-12-01", "completion_date": "2028-12-15", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-09-18T06:40:52.843Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07281716" }, { "nct_id": "NCT06592599", "title": "Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nasopharyngeal Carcinoma" ], "interventions": [ { "name": "Toripalimab", "type": "DRUG" }, { "name": "Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2024-09-03", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-09-18T06:40:52.843Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06592599" }, { "nct_id": "NCT07214987", "title": "PDT For Induction Therapy For Head And Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma", "Head and Neck Cancer Squamous Cell Carcinoma", "Head and Neck Cancer" ], "interventions": [ { "name": "Toripalimab-tpzi", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2026-03-09", "completion_date": "2029-09-01", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-09-18T06:40:52.843Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07214987" }, { "nct_id": "NCT07796126", "title": "Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)" ], "interventions": [ { "name": "Toripalimab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2026-09-30", "completion_date": "2029-05-29", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-18T06:40:52.843Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07796126" }, { "nct_id": "NCT06657144", "title": "A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumor", "Advanced Solid Tumor" ], "interventions": [ { "name": "CHS-114", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" }, { "name": "5 Fluorouracil", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Coherus Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2025-04-01", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-09-18T06:40:52.843Z", "location_count": 20, "location_summary": "Tucson, Arizona • Duarte, California • Aurora, Colorado + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06657144" } ] }